Chemical structures of dopamine, istradefylline, and MB-204 with dopamine D2 and adenosine A2A receptors shown below.

FRAXA-DVI Study Finds Promising Results for Marvel Biosciences’ A2A Receptor Drug in Fragile X Model

FRAXA-DVI study finds Marvel Biosciences’ MB-204, an A2A receptor blocker, improved behavior and cognition in a Fragile X mouse model.

Read More »

Marvel Biosciences Partners with FRAXA to Test MB204 for Fragile X Syndrome

Marvel Biosciences and FRAXA Research Foundation are collaborating to test MB204, a promising new treatment for Fragile X which targets adenosine receptors.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (41)